Future Directions in Imaging for Patients With Prostate Cancer
Closing out his review of imaging modalities in the setting of prostate cancer, Brian Helfand, MD, PhD, looks toward future evolutions in detection and treatment.
Prostate Cancer: Recommendations After Negative Imaging Results
Expert perspective on next steps for physicians and patients following a negative imaging result when recurrent prostate cancer is suspected.
Patient Case 2: A 77-Year-Old Man With Prostate Cancer
Moving on to the second patient case of prostate cancer, Brian Helfand, MD, PhD, shares context for negative imaging results in this setting.
Prostate Cancer: Imaging Considerations for Patients Receiving ADT
A brief discussion on how selection of imaging should be approached for patients receiving androgen deprivation therapy (ADT) for prostate cancer.
Optimizing Selection of Imaging Modalities for Patients With Prostate Cancer
Following his review of available imaging modalities, Brian Helfand, MD, PhD, considers which scans are most appropriate based on patient and disease factors.
Overview of Available Imaging for Patients With Prostate Cancer
A comprehensive review of imaging modalities available to patients with prostate cancer who are suspected of recurrence.
Patient Case 1: A 65-Year-Old Man With Prostate Cancer
Specialist Brian Helfand, MD, PhD, reviews the case of a 65-year-old man with prostate cancer and shares insight on strategies to monitor for recurrence.
Follow-Up After Negative Bone/CT in Prostate Cancer With Molecular Recurrence
Dr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence.
Molecular Recurrence in Oligometastatic Prostate Cancer
An expert panel discusses the challenges of detecting and managing biochemical recurrence in the context of oligometastatic prostate cancer.
Sensitivity of Imaging Modalities to Biochemical Recurrence in Prostate Cancer
Dr Munir Ghesani reviews and comments on data regarding the sensitivity of imaging modalities in detecting biochemical recurrence in prostate cancer.
Case 2: 64-Year-Old Man With Multifocal Prostate Cancer Post-IMRT
Dr Raoul Concepcion leads a panel discussion on a case of a 64-year-old man with multifocal prostate cancer treated with IMRT who refused ADT.
Considerations for Tracer Selection to Assess Biochemical Recurrence in Prostate Cancer
Munir Ghesani, MD, an expert in nuclear medicine, describes the factors that differentiate available tracers and provides guidance on tracer selection.
Imaging Modalities for Evaluating Biochemical Recurrence in Prostate Cancer
An expert panel reacts to polling data on choice of imaging modalities for patients with prostate patients after definitive therapy and share their insights about best practices.
Case 1: 58-Year-Old Man 6 Months Post-Radical Prostatectomy
Raoul Concepcion, MD, presents the case of a 58-year-old man who had a radical prostatectomy 6 months prior and discusses how aspects of the case influence treatment selection.
Considerations for Initiating ADT After Biochemical Recurrence in Prostate Cancer
Experts in prostate cancer discuss considerations for initiating ADT therapy after definitive treatment in patients with prostate cancer in the context of biochemical recurrence.
Defining PSA Nadir After Definitive Therapy in Prostate Cancer
Brian Helfand, MD, PhD, describes the ways in which the PSA nadir can be defined after definitive therapy and the implications of the definition used for patients with prostate cancer.
Best Practices for Monitoring After Definitive Therapy in Prostate Cancer
Dr Judd Moul and colleagues discuss best practices for monitoring patients with prostate cancer after definitive therapy.
Rate of BCR in Prostate Cancer
Dr Raoul Concepcion leads a panel of experts in prostate cancer in setting the stage for case-based discussions of biochemical recurrence.
2 Clarke Drive Cranbury, NJ 08512